

## ASX / Media Release

### Contrast-Induced Acute Kidney Injury Prevention Strategies Featured at TCT 2019

**3 October, 2019 - Minnesota, United States and Melbourne, Australia** – Osprey Medical (ASX: OSP) today provides an update on the TCT 2019 scientific symposium held from 25-29 September in San Francisco, California that featured a number of scientific sessions dedicated to Contrast-Induced Acute Kidney Injury (AKI) in Chronic Kidney Disease (CKD) patients undergoing coronary angiograms.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation (CRF) and the world's premier educational meeting specialising in interventional cardiovascular medicine. TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field. In 2018, TCT was attended by approximately 11,500 healthcare professionals, including approximately 5,700 clinicians.<sup>1</sup>

Osprey Medical CEO Mike McCormick said, "TCT 2019 has shown a significant increase in podium presence this year on the importance of effective prevention strategies in the management of high-risk patients undergoing procedures in the Cath Lab. There was a material increase in content related to CKD and AKI from two sessions at TCT 2018 to a total of five sessions this year."

The "Chronic Kidney Disease: Preventing and Treating Contrast Nephropathy" session featured six clinician-led presentations, with two further sessions comprising a total of 12 presentations on "Renal Insufficiency and Contrast Nephropathy". The "PCI in Chronic Kidney Disease" featured a further four presentations. Contrast minimization with DyeVert was discussed in these sessions as a part of AKI reduction quality initiatives.

Additionally, at the meeting, a scientific symposium entitled "Contrast-Associated Acute Kidney Injury: Preventive Measures that Work in High Risk Patients", co-sponsored by Osprey, GE Healthcare and ABIOMED, Inc., featured several clinical presentations on AKI reduction strategies. A protocol-based approach including DyeVert contrast minimization and monitoring was presented as a real-world example of a multi-department AKI reduction focus that reduced contrast related complications in angiograph patients by 45%.

– ENDS –

#### Contact details:

##### Media

Kyahn Williamson

WE Buchan

M: (61) 401 018 828

[kwilliamson@we-buchan.com](mailto:kwilliamson@we-buchan.com)

##### Investors

Dr Thomas Duthy

Investor Relations

M: (61) 402 493 727

[tduthy@ospreymed.com](mailto:tduthy@ospreymed.com)

##### Company

Doug Schoenberg

VP of Marketing

T: (952) 955 8230

[dschoenberg@ospreymed.com](mailto:dschoenberg@ospreymed.com)

<sup>1</sup> [http://www.crf.org/pdf/meetings/tct/2019/TCT19-Attendee\\_Demographics.pdf](http://www.crf.org/pdf/meetings/tct/2019/TCT19-Attendee_Demographics.pdf)

## **About Osprey Medical (ASX: OSP)**

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (CI-AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

## **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

## **Foreign Ownership Restriction**

Osprey's CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.